Literature DB >> 18796174

Measuring melancholia: the utility of a prototypic symptom approach.

G Parker1, K Fletcher, M Hyett, D Hadzi-Pavlovic, M Barrett, H Synnott.   

Abstract

BACKGROUND: Melancholia has long resisted classification, with many of its suggested markers lacking specificity. The imprecision of depressive symptoms, in addition to self-report biases, has limited the capacity of existing measures to delineate melancholic depression as a distinct subtype. Our aim was to develop a self-report measure differentiating melancholic and non-melancholic depression, weighting differentiation by prototypic symptoms and determining its comparative classification success with a severity-based strategy.
METHOD: Consecutively recruited depressed out-patients (n=228) rated 32 symptoms by prototypic or 'characteristic' relevance (using the Q-sort strategy) and severity [using the Severity-based Depression Rating System (SDRS) strategy]. Clinician diagnosis of melancholic/non-melancholic depression was the criterion measure, but two other formal measures of melancholia (Newcastle and DSM-IV criteria) were also tested.
RESULTS: The prevalence of 'melancholia' ranged from 20.9% to 54.2% across the subtyping measures. The Q-sort measure had the highest overall correct classification rate in differentiating melancholic and non-melancholic depression (81.6%), with such decisions supported by validation analyses.
CONCLUSIONS: In differentiating a melancholic subtype or syndrome, prototypic symptoms should be considered as a potential alternative to severity-based ratings.

Entities:  

Mesh:

Year:  2008        PMID: 18796174     DOI: 10.1017/S0033291708004339

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  8 in total

1.  Depression as a culture-bound syndrome: implications for primary care.

Authors:  Christopher Dowrick
Journal:  Br J Gen Pract       Date:  2013-05       Impact factor: 5.386

2.  Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.

Authors:  R Uher; R H Perlis; N Henigsberg; A Zobel; M Rietschel; O Mors; J Hauser; M Z Dernovsek; D Souery; M Bajs; W Maier; K J Aitchison; A Farmer; P McGuffin
Journal:  Psychol Med       Date:  2011-09-20       Impact factor: 7.723

3.  Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder.

Authors:  Richard Musil; Florian Seemüller; Sebastian Meyer; Ilja Spellmann; Mazda Adli; Michael Bauer; Klaus-Thomas Kronmüller; Peter Brieger; Gerd Laux; Wolfram Bender; Isabella Heuser; Robert Fisher; Wolfgang Gaebel; Rebecca Schennach; Hans-Jürgen Möller; Michael Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2017-06-14       Impact factor: 4.035

4.  Anticipatory reward deficits in melancholia.

Authors:  Huiting Liu; Casey Sarapas; Stewart A Shankman
Journal:  J Abnorm Psychol       Date:  2016-05-12

5.  Melancholic versus non-melancholic depression: differences on cognitive function. A longitudinal study protocol.

Authors:  Saray Monzón; Margalida Gili; Margalida Vives; Maria Jesus Serrano; Natalia Bauza; Rosa Molina; Mauro García-Toro; Joan Salvà; Joan Llobera; Miquel Roca
Journal:  BMC Psychiatry       Date:  2010-06-17       Impact factor: 3.630

6.  Multi-scale motility amplitude associated with suicidal thoughts in major depression.

Authors:  Premananda Indic; Greg Murray; Carlo Maggini; Mario Amore; Tiziana Meschi; Loris Borghi; Ross J Baldessarini; Paola Salvatore
Journal:  PLoS One       Date:  2012-06-12       Impact factor: 3.240

7.  Bias and discriminability during emotional signal detection in melancholic depression.

Authors:  Matthew Hyett; Gordon Parker; Michael Breakspear
Journal:  BMC Psychiatry       Date:  2014-04-27       Impact factor: 3.630

8.  Feature of Heart Rate Variability and Metabolic Mechanism in Female College Students with Depression.

Authors:  Shanguang Zhao; Aiping Chi; Junhu Yan; Chong Yao
Journal:  Biomed Res Int       Date:  2020-02-27       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.